T-DXd Sequencing and Treatment Options in the Tumor-Agnostic Setting
HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.
Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase
Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.
Mirdametinib Yields Significant Responses and HRQOL Improvements in NF1-PN
Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.
Nivolumab Plus Chemotherapy Enhances Responses, Is Well Tolerated in Hodgkin Lymphoma
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Belantamab Mafodotin Combo Significantly Improves OS in Multiple Myeloma
Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.
Determining the Next Steps Forward With BTK Inhibitors in Relapsed CLL
Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.
Denileukin Diftitox Combo Shows Promising ORR and CBR in Solid Tumors
Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.
Adult and Pediatric Oncology Collaboration May Help Standardize Practice
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Transposon-Engineered BAFF CAR-T Cells May Elicit Responses in Lymphoma
Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.
Pimicotinib Significantly Improves Responses Vs Placebo in TGCT
Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study.
Precision Medicine in NSCLC The Power of Molecular Testing
Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.
Managing Treatment Expectations for Patients With Pancreatic Cancer
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
SBRT Emerges as Viable Treatment for Localized Prostate Cancer
Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.
Patient Education for Pancreatic Cancer Risk Factors Is Essential
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
FDA Receives New BLA for Dato-DXd in Advanced EGFR+ NSCLC
Data from TROPION-Lung05, TROPION-Lung01, and TROPION-PanTumor01 support the new BLA for dato-DXd in advanced or metastatic EGFR-mutated NSCLC.
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?
Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.
Camizestrant Significantly Improves PFS in HER2– Breast Cancer
Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.
THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer
Treatment with THIO/cemiplimab was generally well-tolerated among patients with advanced NSCLC in the phase 2 THIO-101 study.
TTFields Plus Temozolomide/Pembrolizumab Controls Tumors in Glioblastoma
Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.
Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma
Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
3 Things You Should Know About Biomarkers in DLBCL
DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Anito-Cel Shows Promising Results in Relapsed/Refractory Multiple Myeloma
Early results from the iMMagine-1 trial show anito-cel as a promising therapy in relapsed/refractory multiple myeloma.
Smoking Cessation Treatment Yields Greater Survival After Cancer Diagnosis
Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.
Novel Immunocytokine Shows Immune Activation in EGFR+ Solid Tumors
Phase 1 data support further assessment of DK210 (EGFR) in solid tumors such as renal cell carcinoma and non–small cell lung cancer.
Data Support Siglec-15 as Possible Signal in NSCLC and Other Solid Tumors
Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Dostarlimab Plus Chemo Yield Strong Survival Results in Metastatic NSCLC
Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.
FDA, EMA Receive Applications for Subcutaneous Daratumumab in Myeloma
Data from the phase 3 AQUILA study support the applications for subcutaneous daratumumab in high-risk smoldering multiple myeloma.
